TW561050B - Pharmaceutical compositions containing an MPL ligand - Google Patents

Pharmaceutical compositions containing an MPL ligand Download PDF

Info

Publication number
TW561050B
TW561050B TW086114078A TW86114078A TW561050B TW 561050 B TW561050 B TW 561050B TW 086114078 A TW086114078 A TW 086114078A TW 86114078 A TW86114078 A TW 86114078A TW 561050 B TW561050 B TW 561050B
Authority
TW
Taiwan
Prior art keywords
item
patent application
composition according
scope
leu
Prior art date
Application number
TW086114078A
Other languages
English (en)
Chinese (zh)
Inventor
David N Brems
Michael J Treuheit
Original Assignee
Amgen Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Amgen Inc filed Critical Amgen Inc
Application granted granted Critical
Publication of TW561050B publication Critical patent/TW561050B/zh

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/524—Thrombopoietin, i.e. C-MPL ligand
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/20—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing sulfur, e.g. dimethyl sulfoxide [DMSO], docusate, sodium lauryl sulfate or aminosulfonic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Genetics & Genomics (AREA)
  • Toxicology (AREA)
  • Hematology (AREA)
  • Biophysics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Diabetes (AREA)
  • Inorganic Chemistry (AREA)
  • Dermatology (AREA)
  • Immunology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
TW086114078A 1996-10-04 1997-09-26 Pharmaceutical compositions containing an MPL ligand TW561050B (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US72612396A 1996-10-04 1996-10-04

Publications (1)

Publication Number Publication Date
TW561050B true TW561050B (en) 2003-11-11

Family

ID=24917340

Family Applications (1)

Application Number Title Priority Date Filing Date
TW086114078A TW561050B (en) 1996-10-04 1997-09-26 Pharmaceutical compositions containing an MPL ligand

Country Status (7)

Country Link
JP (1) JP2001501619A (ja)
KR (1) KR100408229B1 (ja)
CN (1) CN1142940C (ja)
AU (1) AU4344697A (ja)
HK (1) HK1024490A1 (ja)
TW (1) TW561050B (ja)
WO (1) WO1998014476A1 (ja)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8357513B1 (en) 1994-01-03 2013-01-22 Genentech, Inc. Nucleic acids encoding mpl ligand (thrombopoietin) and fragments thereof
US5989538A (en) * 1995-02-15 1999-11-23 Amgen Inc. Mpl ligand analogs
CZ20021186A3 (cs) * 1999-10-04 2002-11-13 Chiron Corporation Farmaceutické prostředky obsahující stabilizovaný kapalný polypeptid
US6495534B2 (en) 2000-05-15 2002-12-17 Pharmacia & Upjohn Spa Stabilized aqueous suspensions for parenteral use
AU2001280161A1 (en) * 2000-08-24 2002-03-04 Kirin Beer Kabushiki Kaisha C-mpl ligand-containing medicinal compositions for increasing platelets and erythrocytes
US7172905B2 (en) 2001-08-07 2007-02-06 The University Of Chicago Polypeptide immobilization
US7250274B2 (en) * 2002-12-13 2007-07-31 Zymogenetics, Inc. IL-21 production in prokaryotic hosts
CN101052312B (zh) 2003-07-07 2013-02-13 希尔氏宠物营养品公司 用于改进宠物中的氧化状态的组合物
US9283260B2 (en) * 2006-04-21 2016-03-15 Amgen Inc. Lyophilized therapeutic peptibody formulations
AU2011265555B2 (en) * 2006-04-21 2016-03-10 Amgen Inc. Lyophilized therapeutic peptibody formulations
MX2009006594A (es) * 2006-12-21 2009-08-12 Amgen Inc Formulaciones de ph regulado y estables que contienen polipeptidos.
AU2014201388C1 (en) * 2006-12-21 2017-02-02 Amgen Inc. Stable Buffered Formulations Containing Polypeptides
CN102552184A (zh) * 2012-02-16 2012-07-11 山东泉港药业有限公司 一种血小板生成素拟肽冻干制剂
KR20230041086A (ko) 2012-09-20 2023-03-23 모르포시스 아게 류마티스 관절염에 대한 치료
MA45381A (fr) * 2016-06-16 2021-04-21 Janssen Vaccines & Prevention Bv Formulation de vaccin contre le vih
AU2018370019A1 (en) * 2017-11-16 2020-05-07 Amgen Inc. Stable compositions of pegylated carfilzomib compounds

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5874075A (en) * 1993-10-06 1999-02-23 Amgen Inc. Stable protein: phospholipid compositions and methods
WO1995026746A1 (en) * 1994-03-31 1995-10-12 Amgen Inc. Compositions and methods for stimulating megakaryocyte growth and differentiation
NZ303588A (en) * 1995-02-15 1999-02-25 Amgen Inc Mpl ligand analogs having one or more changed glycosylation sites uses for these ligand analogs and dna sequences encoding them
US6790439B1 (en) * 1995-06-07 2004-09-14 Zymogenetics, Inc. Thrombopoietin compositions
TW497972B (en) * 1995-06-08 2002-08-11 Kirin Brewery Stable thrombopoietin (TPO)-containing lyophilized compositions
US5879673A (en) * 1996-01-25 1999-03-09 Genentech, Inc. Administration of thrombopoietin on a single day only

Also Published As

Publication number Publication date
CN1239480A (zh) 1999-12-22
AU4344697A (en) 1998-04-24
HK1024490A1 (en) 2000-10-13
CN1142940C (zh) 2004-03-24
WO1998014476A1 (en) 1998-04-09
KR100408229B1 (ko) 2003-12-01
JP2001501619A (ja) 2001-02-06
KR20000048905A (ko) 2000-07-25

Similar Documents

Publication Publication Date Title
TW561050B (en) Pharmaceutical compositions containing an MPL ligand
ES2279649T3 (es) Compuestos trombopoyeticos.
TW400236B (en) Stable protein: phospholipid compositions and methods
US10786551B2 (en) Use of interleukin-22 in the treatment of fatty liver disease
TWI406672B (zh) 生物效力增進的β干擾素聚合物共軛體
JP4516718B2 (ja) 組換えエリスロポエチンと部分的に組合されたｉｌ−１インヒビターおよびｔｎｆアンタゴニストの貧血治療用途
Barbara et al. Tumour necrosis factor‐alpha (TNF‐α): The good, the bad and potentially very effective
Blick et al. Phase I study of recombinant tumor necrosis factor in cancer patients
DE69737266T2 (de) Ob-fusionsprotein enthaltende zusammensetzungen und verfahren
AU621695B2 (en) Stabilized hydrophobic protein formulations
TW565568B (en) Compositions and methods for stimulating megakaryocyte growth and differentiation
DE69631544T2 (de) Fettleibigkeitsprotein (ob) zur erhögung der mageren körpermasse
JPH07505894A (ja) インターフェロンで病気を治療するための副作用の少ない方法および組成物
JP4988562B2 (ja) 安定化したインターフェロン液体製剤
JP2010518079A5 (ja)
KR20020010920A (ko) 각질세포 성장 인자-2 제제
JP2022524754A (ja) 癌を処置するためにｉＲＧＤと共投与される低用量サイトカイン
FR2653020A1 (fr) Utilisation d'un polypeptide ayant l'activite de l'interleukine 2 humaine pour la preparation de compositions pharmaceutiques destinees au traitement des leucemies.
US5635175A (en) Use of CSF-1 to treat viral infections
JP2784401B2 (ja) 慢性骨髄性白血病の治療方法
CN105294852B (zh) 聚乙二醇与肿瘤坏死因子α或其类似物的偶联物及其医药用途
Vogels et al. Interleukin-1 (IL-1)-induced resistance to bacterial infection: role of the type I IL-1 receptor
JP5798628B2 (ja) ウシ顆粒球コロニー刺激因子のための製剤およびその変異体
US20110071077A1 (en) Thrombopoietic Compounds
EP1033997B1 (en) Method of mobilizing hematopoietic stem cells

Legal Events

Date Code Title Description
GD4A Issue of patent certificate for granted invention patent
MM4A Annulment or lapse of patent due to non-payment of fees